• Tidak ada hasil yang ditemukan

links.lww.com/INF/A801

N/A
N/A
Protected

Academic year: 2024

Membagikan "links.lww.com/INF/A801"

Copied!
2
0
0

Teks penuh

(1)

Supplemental Digital Content 1. Risk of early measles infection: Susceptibility and morbidity indicators

Risk factors 4.5 months: Risk of infection % (cases/N) 4.5-9 months: Rate of infection (cases/person- years (pyrs))

Ratio (95% CI)

Specific

susceptibility and herd immunity

Sex Female Male

Before 4.5 months 3.8 (30/781) 3.8 (28/743) 1.03 (0.62-1.71) 4.5 to 9 months 0.39 (53/135 pyrs) 0.33 (45/135 pyrs) 1.17 (0.79-1.73)

Mother’s age 15-24 25-44

Before 4.5 months 4.9 (36/739) 2.9 (21/733) 1.67 (0.99-2.82) 4.5 to 9 months 0.42 (54/128 pyrs) 0.29 (39/136 pyrs) 1.53 (1.02-2.31)

District Cuntum Old districts

Before 4.5 months 4.1 (22/543) 3.7 (36/981) 1.08 (0.64-1.82) 4.5 to 9 months 0.44 (41/93 pyrs) 0.32 (57/176 pyrs) 1.36 (0.91-2.03) Non-specific

susceptibility indicators

MUAC <130mm 130mm+

4.5 to 9 months 0.40 (18/45 pyrs) 0.36 (80/225 pyrs) 1.12 (0.67-1.86) Weight-Height- z-score WHZ <-2 WHZ >=-2

4.5 to 9 months 0.39 (5/13 pyrs) 0.36 (92/257 pyrs) 1.05 (0.43-2.57) Low birth weight <2.5 kg => 2.5 kg

Before 4.5 months 3.3 (3/90) 4.0 (37/919) 0.71 (0.25-2.06)

4.5 to 9 months 0.40 (5/13 pyrs) 0.34 (58/173 pyrs) 1.20 (0.50-2.89)

Breastfeeding No Yes

Before 4.5 months 0 (0/40) 3.9 (57/1480) 0

4.5 to 9 months 0.76 (7/9 pyrs) 0.35 (91/260 pyrs) 2.12 (1.06-4.26)

BCG Scar No Yes

Before 4.5 months 7.3 (20/275) 3.1 (38/1242) 2.30 (1.36-3.90) 4.5 to 9 months 0.38 (17/44 pyrs) 0.36 (81/225 pyrs) 1.09 (0.64-1.85) Morbidity indicators

at 4½ months

(2)

Fever at enrollment Yes No

4.5 to 9 months 0.66 (26/39 pyrs) 0.32 (72/228 pyrs) 2.02 (1.27-3.20) Respiratory illness at

enrollment

Yes No

4.5 to 9 months 0.99 (13/13 pyrs) 0.33 (84/255 pyrs) 2.87 (1.62-5.07) Diarrhoea at

enrollment

Yes No

4.5 to 9 months 0.24 (5/21 pyrs) 0.38 (93/245 pyrs) 0.62 (0.25-1.55)

Referensi

Dokumen terkait

[r]

[r]

Supplementary Table 3: Decline in incidence of tuberculosis TB from 2005 to 2009 in human immunodeficiency virus HIV -infected and -uninfected African children 3 months

ALT, alanine aminotransferase; AST, aspartate aminotransferase; GI, gastrointestinal; IV, intravenous; SoC,

† Other symptoms included:, weight loss, decreased oral intake, vertigo, ataxia, metabolic acidosis, inability to walk, syncope, severe dehydration, sepsis, decreased oral intake and

Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study... Prospective study of renal

Supplementary table 2a: Multilevel univariable logistic regression analysis showing factors associated with different respiratory

a Includes structural defects of the respiratory tract and asthma b Includes history of cancer, transplant, and other primary or secondary immunodeficiencies